{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","value":"1"}]}],"title":"Grade 3 amylase increased"},{"categories":[{"measurements":[{"groupId":"OG003","value":"1"}]}],"title":"Grade 4 lipase increased"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"description":"Cohort 3b included participants with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m\\^2) loading dose of cetuximab by infusion and then 200 mg/m\\^2 weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m\\^2 loading dose of cetuximab and then 250 mg/m\\^2 weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m\\^2 loading dose of cetuximab and then 250 mg/m\\^2 weekly. Reported here are type and number of dose limited toxicities observed.","groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"OG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"OG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"OG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"OG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"OG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"OG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"OG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"OG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"OG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"}],"paramType":"NUMBER","populationDescription":"All participants from Cohort 3b who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Number of Dose-limiting Toxicities of Vemurafenib in Combination With Cetuximab","type":"SECONDARY","unitOfMeasure":"dose-limiting toxicities"}